Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-209
- Development stage
- Phase 2
- Lead developer
- Addpharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**AD-209** is an oral low-dose fixed-dose antihypertensive combination developed by Addpharma for essential hypertension. Each tablet contains telmisartan 20 mg, amlodipine 2.5 mg, and chlorthalidone 6.25 mg. Telmisartan blocks angiotensin II type 1 receptors, amlodipine inhibits L-type calcium channels in vascular smooth muscle, and chlorthalidone inhibits renal sodium-chloride transport, providing complementary blood-pressure-lowering mechanisms. The program has completed Phase 2 studies and has been evaluated in a Phase 3 trial for essential hypertension. ([academic.oup.com](https://academic.oup.com/eurheartj/article/46/Supplement_1/ehaf784.3392/8309044))
- Brand names
- Truset 20/2.5/6.25 mg
- Other names
- AD-209 TabAD209 TabAD 209 Tab
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on AD-209.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-209.